Loading clinical trials...
Loading clinical trials...
Mepolizumab Long-term Access Programme for Subjects Who Participated in Study MEA115921 (Placebo-controlled Study of Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis in Subjects Receiving Standard-of-care Therapy)
Conditions
Interventions
Mepolizumab
Prednisolone
Locations
32
United States
GSK Investigational Site
Denver, Colorado, United States
GSK Investigational Site
Bethesda, Maryland, United States
GSK Investigational Site
Boston, Massachusetts, United States
GSK Investigational Site
Boston, Massachusetts, United States
GSK Investigational Site
St Louis, Missouri, United States
GSK Investigational Site
New York, New York, United States
Start Date
April 14, 2015
Primary Completion Date
February 16, 2023
Completion Date
February 16, 2023
Last Updated
March 12, 2024
NCT03004326
NCT05979051
NCT06046222
NCT07343661
NCT05263934
NCT03557060
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions